Cord Blood S100B Protein Concentration in Neonates With Fetal Growth Restriction
Launched by INSTITUTE OF MOTHER AND CHILD, WARSAW, POLAND · Mar 24, 2025
Trial Information
Current as of April 30, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the levels of a protein called S100B in the cord blood of newborns, specifically those who have been diagnosed with fetal growth restriction (FGR) compared to those with normal growth. S100B is a marker that can indicate damage to the brain, and measuring its levels soon after birth could help identify babies at risk for developmental issues early on. The goal is to see if testing for S100B can help doctors provide timely care and improve outcomes for these infants.
To participate in this study, women must be at least 37 weeks pregnant with a single baby. Those with FGR will be included, while those with certain health conditions, such as diabetes or infections, will be excluded. Participants will have their baby's cord blood tested after birth and will undergo ultrasound checks of blood flow before delivery. This research aims to better understand how S100B levels relate to the health of the baby and potentially enhance care for infants facing challenges due to FGR.
Gender
FEMALE
Eligibility criteria
- Study Group - Inclusion Criteria:
- • 1. Women with a full-term pregnancy (≥37 weeks of gestation), singleton.
- • 2. Pregnancy complicated by FGR.
- Study Group - Exclusion Criteria:
- 1. Antenatal (at recruitment):
- • Maternal conditions that may affect the blood flow in placental vessels, including smoking, use of illicit stimulant substances, or pregestational diabetes.
- • Maternal depression requiring pharmacological treatment (e.g., SSRIs).
- 2. Intrapartum:
- • Factors indicating a possible intrauterine infection, such as amniotic fluid leakage for more than 15 hours, spontaneous preterm labor, diagnosed intrauterine infection, or symptoms of infection in the mother.
- • Prolonged labor lasting more than 15 hours.
- Control Group - Inclusion Criteria:
- • 1. Women with a full-term pregnancy (≥37 weeks of gestation), singleton.
- • 2. Pregnancy not complicated by FGR.
- Control Group - Exclusion Criteria:
- 1. Antenatal (at recruitment):
- • Maternal conditions that may affect placental blood flow, such as smoking, use of illicit stimulant substances, pregestational diabetes, or chronic hypertension.
- • Maternal depression requiring pharmacological treatment (e.g., SSRIs).
- • Risk factors for intrauterine HI, including abnormal fetal blood flow parameters on ultrasound, abnormal CTG recordings, or the need for intrauterine transfusion.
- 2. Intrapartum:
- • Indicators of possible intrauterine infection, such as amniotic fluid leakage for more than 15 hours, spontaneous preterm delivery, diagnosed intrauterine infection, or maternal symptoms of infection.
- • Risk factors for perinatal HI.
- • Prolonged labor lasting more than 15 hours (counted from the onset of regular uterine contractions).
- • Birth weight below the 10th percentile or above the 90th percentile.
- • Apgar score less than 8 at the 1st, 3rd, 5th, or 10th minute of life.
- • Abnormal umbilical cord blood gas analysis results, defined as pH \< 7.15 or BE \< -9.3 mmol/l.
- 3. Postnatal:
- • Neonatal anemia requiring a top-up transfusion within the first 24 hours of life
About Institute Of Mother And Child, Warsaw, Poland
The Institute of Mother and Child, located in Warsaw, Poland, is a leading research and clinical institution dedicated to improving maternal and child health outcomes. With a strong emphasis on innovative medical research, the institute conducts a wide range of clinical trials aimed at advancing pediatric and obstetric care. Its multidisciplinary team of experts collaborates closely with healthcare professionals and academic institutions to ensure the highest standards of scientific rigor and ethical integrity in all studies. By fostering a collaborative environment, the Institute of Mother and Child strives to translate research findings into effective clinical practices that enhance the well-being of mothers and children both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Warsaw, , Poland
Patients applied
Trial Officials
Agnieszka A. Drozdowska-Szymczak, MD, PhD
Principal Investigator
Institute of Mother and Child in Warsaw, Poland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported